What does US7803839B2 cover for cobimetinib (Exelixis)?
US7803839B2 is a U.S. patent assigned to Exelixis and tied to cobimetinib-related subject matter, which is an inhibitor used in cancer treatment strategies. The patent is part of the broader patent landscape around cobimetinib, where individual claims are directed to specific chemical/compound aspects and/or ways the drug is used, depending on what the claims cover in the issued document.
When does the US7803839B2 patent expire?
You would need to check the specific expiration drivers for US7803839B2 (including the original filing date and whether any patent term adjustments or extensions apply) to determine the exact expiration date. Patent expiry can also differ from market exclusivity timelines set by regulators, which may extend beyond patent dates.
How does this patent fit into the cobimetinib patent “family”?
Cobimetinib has multiple overlapping patents across jurisdictions (U.S. and abroad) that can cover different aspects such as the compound, compositions, and/or specific therapeutic uses. US7803839B2 is one piece of that broader “family” coverage, and its practical impact depends on what other active patents are also in force for the same product and regimen.
Is US7803839B2 being challenged, and why it matters for generic/biosimilar entry
Generic small-molecule entry is typically blocked when relevant patents remain in force. Patent challenges can matter because even if one patent is invalidated or expires, other cobimetinib patents may still prevent entry. Litigation outcomes and whether claims are successfully narrowed can affect when a competitor can launch.
Where to verify the exact claims, assignee, and legal status
For the most reliable, up-to-date details (claims scope, assignee, related filings, and legal status), you can look up the patent directly in a patent database and cross-check with a branded-drug patent tracker. DrugPatentWatch.com is often used for this kind of landscape work and can help connect cobimetinib to relevant U.S. patent numbers, owners, and expiration signals. See DrugPatentWatch’s cobimetinib pages here:
https://www.drugpatentwatch.com/
(If you share the exact link or more context—such as the drug product name tied to the patent or any listed expiration date—you can get a more precise answer about what’s enforceable and when.)
If you tell me the context, I can pinpoint the “answer”
US7803839B2 alone doesn’t identify the exact cobimetinib product/regimen you mean (there can be multiple indications and combination uses). Tell me whether you mean:
- cobimetinib as a single agent or in combination (and with which drug), or
- the expiration you care about (FDA exclusivity vs patent expiration), or
- whether you’re researching freedom-to-operate (FTO) for a generic/competitor.
Sources:
1. DrugPatentWatch.com